Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore the intersection of human genetics and pharmaceutical drug development in this keynote presentation from the Variant to Function (V2F) Symposium at the Broad Institute. Discover how billion-dollar investment decisions are made in drug research and development through the lens of human genetics, as presented by Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb. Learn about the critical process of translating genetic associations into actionable therapeutic targets, including the development of biomarkers and assays for patient stratification. Gain insights into genetically-informed approaches that are accelerating healthcare innovation and understand the strategic considerations behind major pharmaceutical investments. The presentation is part of a comprehensive scientific conference focused on bridging the gap between genetic discoveries and practical therapeutic applications, co-chaired by leading researchers Melina Claussnitzer and Kasper Lage at the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease.
